Prosztatarák: vizsgálatok itt: Lengyelország
39 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Bydgoszcz, Grudziądz, Kielce, Koszalin, Siedlce, Szczecin
- Életkor
- 18 év and over
- People
- 1310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - 1. fázisCsak meghívásosA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Cracow, Gdansk, Katowice, Skorzewo
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - 3. fázisTaking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Bialystok, Bydgoszcz, Koszalin, Warsaw
- Életkor
- 18 év and over
- People
- 1203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - 3. fázisTaking peopleA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Cracow, Grudziądz, Koszalin, Lublin, Opole, Piotrkow Trybunalski, Torun, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - 3. fázisTaking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Bydgoszcz, Cracow, Katowice, Poznan, Siedlce, Warsaw
- Életkor
- 18 év and over
- People
- 1440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - 1/2. fázisTaking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Krakow, Lódz, Szczecin
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - 1/2. fázisTaking peopleStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Koszalin, Piotrkow Trybunalski, Przemyśl
- Életkor
- 18 év to 130 év
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - No phaseTaking peopleA Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
- Where
- Many Locations
- Életkor
- 18 év and over
- People
- 1600 worldwide
- Run by
- Bayer
See details and how to joinNCT07344779 - 3. fázisTaking peopleAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Gdansk, Krakow, Warsaw
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 2. fázisTaking people177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
- Where
- Gliwice
- Életkor
- 18 év and over
- People
- 200
- Run by
- Maria Sklodowska-Curie National Research Institute of Oncology
See details and how to joinNCT06449781 · EU 2023-504912-13-00 - 3. fázisTaking peopleA Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Where
- Bialystok, Cracow, Gliwice, Kielce, Lodz, Lublin, Poznan, Siedlce, Skorzewo, Sosnowiec, Szczecin, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 736 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Bydgoszcz, Cracow, Koszalin, Warsaw
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 3. fázisTaking peopleSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Cracow, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Cracow, Gdynia, Gliwice, Koszalin, Piotrkow Trybunalski, Poznan, Rzeszow, Warsaw
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisTaking peopleThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Cracow, Gdynia, Koszalin, Lublin, Poznan, Rzeszow, Szczecin, Wroclaw, Wrocław
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 1/2. fázisTaking peopleA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Gdansk, Koszalin, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - 1/2. fázisTaking peopleAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
- Where
- Poznan
- Életkor
- 18 év and over
- People
- 188 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Bydgoszcz, Gdansk, Otwock, Poznan, Wroclaw
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Cracow, Gliwice, Warsaw
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseTaking peoplePSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer
- Where
- Zamość
- Életkor
- 18 év and over
- People
- 1000
- Run by
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
See details and how to joinNCT07691697 - 2. fázisTaking peopleA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Where
- Gdansk, Gliwice, Myslowice, Otwock
- Életkor
- 18 év and over
- People
- 218 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00 - 1. fázisTaking peopleStudy to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
- Where
- Cracow, Gdansk, Lodz, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Duke Street Bio Ltd
See details and how to joinNCT06458712 · EU 2023-508805-26-00 - 1/2. fázisTaking peopleA Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
- Where
- Cracow, Gdansk, Warsaw
- Életkor
- 18 év and over
- People
- 52 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Gdansk, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - 3. fázisNot yet taking people in LengyelországA clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate cancer
- Where
- Piotrkow Trybunalski
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
See details and how to joinNCT03520478 · EU 2024-515194-10-00